natgillin/translations-raw huggingface dataset:
Ingen klinisk signifikant farmakokinetisk interaktion.
No clinically significant pharmacokinetic interaction The geometric mean Cmin for
Ingen klinisk signifikant reduktion i glimepirid AUC og Cmax blev observeret efter gentagne doser af rosiglitazon i 8 dage hos raske voksne personer.
No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of rosiglitazone for eight days in healthy adult subjects.
Ingen klinisk signifikante forskelle blev set, da sikkerhedsdata blev analyseret i henhold til køn og race.
No clinically significant differences were seen when the safety data were analysed by gender or race.
Ingen klinisk signifikante interaktioner med andre lægemidler er rapporteret for follitropin alfa.
No other clinically significant drug interaction has been reported during follitropin alfa therapy.
Ingen klinisk signifikante lokale eller systemiske effekter blev observeret i topikale okulære langtidsundersøgelser hos kaniner.
No clinically significant local or systemic effects were observed in long-term topical ocular studies in rabbits.
Ingen klinisk signifikante ændringer er blevet set i clearance for doser på fra 5 til 60 mg.
No clinically significant changes have been seen in clearance for doses ranging from 5 to 60 mg.
Ingen klinisk signifikante ændringer i det gennemsnitlige QTc-interval (dvs. > 20 msek.) fra baseline blev konstateret i studiet.
No clinically significant changes in the mean QTc interval (i.e., > 20 ms) from baseline were detected in the study.
INGEN klumper, ensartet uklar injektionsvæske
NO Clumps, uniformly cloudy
Ingen knærefleks eller respons på at blive knebet
Absence of knee reflex or a response to a pinch
Ingen kvalme (Likert skala) p-værdic
No Nausea (Likert
Ingen kvalme (Likert skala) p-værdic
No Nausea (Likert Scale) p-value c
Ingen kvalme (Likert skala) p-værdic
No Nausea (Likert Scale) p-valuec
Ingen levermetastaser: ALT/AST ≤ 3 x ULN
No liver metastases: ALT/AST ≤3 x ULN
Ingen lægemiddelinteraktioner blev observeret i feltstudier, hvor oclacitinib blev administreret samtidig med veterinærlægemidler så som endo- og ektoparasitdræbende lægemidler, antimikrobielle lægemidler og antiinflammatoriske lægemidler.
No drug interactions were observed in field studies where oclacitinib was administered concomitantly with veterinary medicinal products such as endo- and ectoparasiticides, antimicrobials and anti- inflammatories.
Ingen lægemiddelinteraktioner blev observeret i feltstudier, hvor oclacitinib blev administreret samtidig med veterinærlægemidler så som endo- og ektoparasiticider, antimikrobielle lægemidler og antiinflammatoriske lægemidler.
No drug interactions were observed in field studies where oclacitinib was administered concomitantly with veterinary medicinal products such as endo- and ectoparasiticides, antimicrobials and anti- inflammatories.
Ingen mutation
No mutation
Ingen NOTEL (No Observed Toxic Effect Level) kunne bestemmes i de prækliniske studier med undtagelse af en 7-dages administration af 0,1 g/kg i aber.
No NOTEL (No Observed Toxic Effect Level) could be established in the preclinical studies with the exception of a 7-day administration of 0.1 µg/kg in monkeys.
Ingen ny ENF*
No New ENF
Ingen nye sikkerhedsfund blev identifieret i 192- ugers-analysen af behandlingsnaive patienter, hvor den gennemsnitlige behandlingstid med PREZISTA/ritonavir 800/100 mg en gang dagligt var 162,5 uger.
No new safety findings were identified in the 192 week analysis of the treatment- naïve subjects in which the mean treatment duration of PREZISTA/ritonavir 800/100 mg once daily was 162.5 weeks.
Ingen nye sikkerhedsfund blev identifieret i 192- ugers-analysen af behandlingsnaive patienter, hvor den gennemsnitlige behandlingstid med PREZISTA/ritonavir 800/100 mg en gang dagligt var 162,5 uger.
No new safety findings were identified in the 192 week analysis of the treatment-naïve subjects in which the mean treatment duration of PREZISTA/ritonavir 800/100 mg once daily was 162.5 weeks.
Ingen nye sikkerhedssignaler blev identificeret blandt personer, som blev genbehandlet med Xiapex.
No new safety signals were identified among subjects who were retreated with Xiapex.
Ingen nye uventede sikkerhedsfund blev observeret i dette studie.
No new unexpected safety signals were observed in this trial.
Ingen opkastning
No vomiting
Ingen opkastning (ingen opkastning episoder uden hensyn til brug af erstatningsterapi)
No emesis (no emetic episodes regardless of use of rescue therapy)
Ingen opkastning (ingen opkastning uden hensyn til brug af erstatningsterapi)
No emesis (no emetic episodes regardless of use of rescue therapy)
Ingen opkastning§ – total fase
No vomiting§ – Overall phase
Ingen oplysninger.
Not applicable.
Ingen overvejelse af artenimols fototoksicitet er nødvendigt, da det ikke absorberer i intervallet 290-700 nm.
There are no phototoxicity concerns withartenimol, as it does not absorb in the range of 290-700 nm.
ingen patienter
patients exhibited withdrawal
Ingen patienter afbrød behandlingen med forsøgslægemidlet i SBR-armen.
No patients discontinued from the study due to a TEAE in the SBR arm.
Ingen patienter afbrød behandlingen med rilpivirin på grund af bivirkninger.
No patients discontinued rilpivirine due to adverse reactions.
Ingen patienter blev diagnosticeret med myelodysplastisk syndrom i nogen af behandlingsgrupperne.
No patient was diagnosed with myelodysplastic syndrome in either treatment groups.
Ingen patienter havde behov for ny dialyse under Soliris- behandlingen.
No patient required new dialysis with Soliris.
Ingen patienter havde en absolut QTcF >500 msek., mens de tog studiemedicinen.
No patient had an absolute QTcF >500 msec while on the study medicinal product.
Ingen patienter havde en QTc-værdi >500 msek.
No patients had a QTc interval >500 msec.
Ingen patienter havde en QTcF-værdi >500 ms.
No patient had a QTcF value >500 ms.
Ingen patienter havde LVEF <45 % under behandlingen eller en absolut reduktion i LVEF på mere end 15 %.
No patient had a LVEF of <45% during treatment nor an absolute reduction in LVEF of more than 15%.
Ingen patienter havde maksimum QTcF ≥480 ms.
No patients had a maximum QTcF ≥480 msec.
Ingen patienter havde QTcF >480 msek.
No patient had a QTcF >480 msec.
Ingen patienter i begge grupper udviklede cirrhosis.
No patients in either group progressed to cirrhosis.
Ingen patienter i nogen af grupperne viste en QTc> 60 msek.
No patient in either group developed a ΔQTc >60 msec.
Ingen patienter i SBR-armen udgik af studiet pga.
No patients discontinued from the study due to a TEAE in the SBR arm.
Ingen patienter oplevede et QTc-interval større end Grad 2 (CTCAE-version 3,0).
No subjects experienced an effect on the QTc interval greater than Grade 2 (CTCAE version 3.0).
Ingen patienter på  65 år deltog i de kliniske forsøg.
No patients of ≥ 65 years of age were included in clinical trials.
Ingen patienter seponerede behandlingen med studiemedicinen pga. bivirkninger i løbet af studiets blindede behandlingsfase.
No patients discontinued study drug because of ADRs during the blinded study treatment phase.
Ingen patienter seponerede behandlingen med studiemedicinen pga. bivirkninger.
No patients discontinued study drug due to ADRs.
Ingen patienter udviklede grad 4 trombocytopeni.
No patient developed grade4 thrombocytopenia.
Ingen patienter udviklede HAHA mod Gazyvaro under eller efter behandling med Gazyvaro.
No patient developed HAHA to Gazyvaro during or following Gazyvaro treatment.
Ingen patienter udviklede infusionsrelaterede reaktioner eller peri–infusionshypersensitivitet eller anafylaktiske reaktioner.
None had any infusion-related or peri-infusional hypersensitivity or anaphylactic reactions.
Ingen patienter udviste hurtig forværring af Gauchers sygdom type 1 efter skift til Zavesca- monoterapi.
No patient showed rapid deterioration of type 1 Gaucher disease following the switch to Zavesca monotherapy.
Ingen patienter, som blev behandlet med trametinib i kombination med dabrafenib, i fase III-studiet MEK115306 havde alvorlig QTcB-forlængelse til > 500 ms.
In the Phase III study MEK115306 no patients treated with trametinib in combination with dabrafenib had worst-case QTcB prolongation to
Ingen primær IN- mutation1
No primary IN mutation1
Ingen psykiatriske co- morbiditeter
No psychiatric comorbidities
Ingen rapporteret
None reported
Ingen reduktion i OCS/ manglende astmakontrol/ seponering af behandling
No decrease in OCS/lack of asthma control/ withdrawal from treatment
INGEN REGISTRE- RING
NO ENTRY
Ingen relevante.
Not applicable.
Ingen respons
Nonresponder
Ingen respons ved Intet Negativ behandling vedvarend prædiktiv s uge e respons værdi
No response at No Negative treatment sustained predictive week response value
Ingen samlede forskelle blev observeret i sikkerhedsprofilen hos ældre patienter ≥ 65 år, og hos yngre voksne patienter < 65 år i de kliniske studier.
No overall differences were observed in the safety profile of elderly patients ≥ 65 years of age and younger adult patients < 65 years of age in the clinical studies.
Ingen signifikant kvalme
No significant nausea
Ingen signifikant virkning på
No significant effect on rifabutin
Ingen signifikant virkning på rifabutin og Viramune gennemsnitlige farmakokinetiske (PK) parametre er set.
No significant effect on rifabutin and Viramune mean PK parameters is
ingen sikkerhedsdata for endometriet for uafbrudte perioder over 3 måneder.
absence of safety data on the endometrium for continuous treatment longer than 3 months.
Ingen speciel dosisjustering er påkrævet hos patienter over 65 år.
No special dose adjustment is required in patients aged > 65 years old.
Ingen specielle opbevaringsbetingelser
No special storage conditions.
Ingen specifik dosisjustering er påkrævet for ældre patienter (i alderen ≥ 65 år).
No specific dose adjustment is required for elderly patients (aged ≥ 65 years).
Ingen specifik modgift er kendt.
There is no known specific antidote.
Ingen større alders- eller væ gtrelaterede forskelle i elimination eller fordelingsvolumen sås hos patienter med reumatoid arthritis.
No major age- or weight-related differences in clearance or volume of distribution were observed in rheumatoid arthritis patients.
Ingen supplerende prævention er nødvendig.
Back-up contraception is not needed.
Ingen sådan forøgelse af tmax observeredes, når atorvastatin blev administreret om aftenen og lixisenatid om morgenen, men AUC og Cmax for atorvastatin øgedes med henholdsvis 27 % og 66 %.
No such increase for tmax was observed when atorvastatin was administered in the evening and lixisenatide in the morning but the AUC and Cmax of atorvastatin were increased by 27% and 66% respectively.
Ingen sæddonation under behandling og i 2 måneder efter Erivedge-behandling
Not to donate semen during treatment and for 2 months after the final dose
Ingen sæddonation under behandling og i 2 måneder efter sidste dosis
Not to donate semen during treatment and for 2 months after the final dose
Ingen særlige fertilitetsstudier er blevet udført for mifamurtid (se afsnit 5.3).
No dedicated fertility studies have been conducted with mifamurtide (see section 5.3).
Ingen særlige forholdsregler
Not applicable
Ingen særlige forholdsregler
Not applicable.
Ingen særlige forholdsregler ved bortskaffelse
No special requirements.
Ingen særlige forholdsregler ved bortskaffelse.
There are no special requirements for disposal.
Ingen særlige forholdsregler vedrørende opbevaringen.
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY
Ingen særlige forholdsregler vedrørende opbevaringen.
This medicinal product does not require any special storage conditions.
Ingen særlige forholdsregler vedrørende opbevaringen.
This medicine does not require any special storage conditions.
Ingen særlige forholdsregler vedrørende opbevaringen.
This veterinary medicinal product does not require any special storage conditions.
Ingen tedeglutidakkumulation observeres efter gentagen subkutan administration.
No accumulation of teduglutide was observed following repeated subcutaneous administration.
Ingen tegn på blaster i kredsløb eller ekstramedullær sygdom
No evidence of circulating blasts or extramedullary disease
Ingen tegn på lægemiddel- relateret lokal irritabilitet eller inkompatibilitet blev bemærket hos hunde efter intravenøs, intra- arteriel og paravenøs injektion, når cetrorelix blev givet i doser klart over den tiltænkte kliniske anvendelse på mennesker.
No signs of medicinal product-related local irritation or incompatibility were noted in dogs after intravenous, intra-arterial and paravenous injection when cetrorelix was administered in doses clearly above the intended clinical use in man.
Ingen teratogen effekt sås hos kaniner ved 300 mg/kg/dag (ca.
No teratogenic effects were seen in rabbits at
Ingen tidligere bortezomib-eksponering
No prior immunomodulatory exposure
Ingen tidligere immunmodulerende eksponering
18.4 [14.1, 23.1]
Ingen tidligere nukleosid-behandling
Nucleoside Naive
Ingen tidsafhæ ngig farmakokinetik sås.
No time-dependency of the Pharmacokinetics was observed.
Ingen tilfælde af overdosis er rapporteret hos patienter med erhvervet hæmofili eller Glanzmanns trombasteni.
No cases of overdose have been reported in patients with acquired haemophilia or Glanzmann’s thrombasthenia.
Ingen tilgængelige data.
No data are available.
Ingen tilgængelige oplysninger.
No information is available.
Ingen transfusion
No transfusion
Ingen undersøgelser er udført for at bestemme effekten af på metabolisering eller elimination af andre lægemidler.
No studies have been conducted to determine the effect of TMZ on the metabolism or elimination of other medicinal products.
Ingen undersøgelser er udført for at bestemme TMZ’s effekt på metabolisering eller elimination af andre lægemidler.
No studies have been conducted to determine the effect of TMZ on the metabolism or elimination of other medicinal products.
Ingen undersøgelser er udført omfattende fertilitet og den tidlige embryonale udvikling (se afsnit 5.3)
No studies were performed that covered fertility and early embryonic development (see section 5.3).
Ingen uønskede reaktioner blev observeret efter administration af en overdosis (10 x dosis)
No adverse reactions were observed after the administration of an overdose (10x the dose).
Ingen virkning = 1,00
No effect = 1.00
Ingen virkning = 1,00.
No effect = 1.00.
Ingen virologiske data i analysevinduet omkring uge 48
No virologic data at Weeks 48 window
Ingen virologiske data i uge 48- eller uge 144-vinduet
No virologic data in week 48 or 144 window
Ingen virologiske data i uge 48-vinduet
No virologic data in week 48 window
Ingen virologiske data ved uge 48- eller 96-vinduet
No virologic data at Week 48 or 96 window
Ingen virologiske data ved uge 48- eller uge 144- vinduet
No virologic data at Week 48 or 144 window
Ingen virologiske data ved uge 48- eller uge 96-vinduet
No virologic data at Week 48 or 96 window
Ingen virologiske data ved uge 48- eller uge 96-vinduet
No virologic data at week 48 or week 96 window
Ingen virologiske data ved uge 48-vinduet
No virologic data at Week 48 window
Ingen yderligere dosis hvis den sidste dosis blev administreret subkutant inden for 8 timer før ballonudvidelse.
No additional dose if the last dose was administered subcutaneously before the end of 8 hours prior to filling the balloon,
Ingen yderligere dosis hvis den sidste dosis var blevet administreret subkutant inden for 8 timer før ballonudvidelse.
No additional dose if the last dose was administered subcutaneously before the end of 8 hours prior to filling the balloon,
Ingen yderligere dosis, hvis den sidste dosis var blevet administreret subkutant inden for 8 timer før ballonudvidelse.
No additional dose if the last dose was administered subcutaneously before the end of 8 hours prior to filling the balloon,
Ingen ændring af dosis bør være nødvendig hos patienter med let nedsat nyrefunktion.
No posology adjustment is required in patients with mild hepatic impairment.
Ingen ændring i dosis eller doseringsplan.
No change in dose or schedule.
Ingen, grad 1-2, grad 3-4*
None Grade 1-2 Grade 3-4
Ingen.
None known.
Ingen.
Zero days.
Inhalation
Inhalation use
Inhalation af damp og kontakt med hud og slimhinder, især i øjnene, skal undgås.
Inhalation of the vapour and contact with the skin and mucosa, particularly that of the eyes, must be avoided.
Inhalation Inhalation Inhalation Inhalation
Inhalation use Inhalation use Inhalation use Inhalation use
inhalation om morgenen og 1 inhalation om aftenen eller inhalationer om morgenen eller
inhalation in the morning and 1 inhalation in the evening or inhalations in the morning or
Inhalations-bronkodilatorer
Inhaled bronchodilators
Inhalationsantibiotika, hvis det er en del af din behandlingsrutine
Inhaled antibiotics if this is part of your treatment routine
Inhalationsbehandling med nitrogenoxid skal opretholdes ved 5 ppm, indtil der ses en forbedring i oxygenmætningen, således at FiO2 (fraktion af inspireret oxygen) er < 0,60.
Inhaled nitric oxide therapy should be maintained at 5 ppm until there is improvement in the neonate’s oxygenation such that the FiO2 (fraction of inspired oxygen) < 0.60.
Inhalationsbrug
Inhalation use
Inhalationsgas.
Inhalation gas.
Inhalationspulver i
Inhalation powder,
Inhalationspulver i kapsel
Inhalation powder, hard capsules
Inhalationspulver i kapsel (inhalationspulver).
Inhalation powder, hard capsule (inhalation powder)
Inhalationspulver i kapsler
hard capsule Inhalation powder, hard capsule
Inhalationspulver i kapsler
Inhalation powder,
Inhalationspulver Inhalationspulver
Inhalation powder
Inhalationspulver, afdelt
Inhalation powder pre-dispensed
Inhalationspulver, afdelt
Inhalation powder, pre
Inhalationspulver, afdelt (Inhalationspulver)
Inhalation powder, pre-dispensed (Inhalation powder).
Inhalationspulver, hårde kapsler
Inhalation powder, hard capsules
Inhalationstoksicitetsforsøg på rotter og aber i op til 6 måneder viser ingen speciel risiko for luftrøret på grund af insulininhalationspulveret.
Inhalation toxicity studies in rats and monkeys for up to 6 months gave no evidence for a special risk to the respiratory tract due to insulin inhalation powder.
Inhalationsvæske til nebulisator, opløsning
Nebuliser solution
Inhalationsvæske til nebulisator, opløsning
Nebuliser solution.
Inhalationsvæske til nebulisator, opløsning 4 ampuller
Nebuliser solution 4 ampoules
Inhalationsvæske til nebulisator, opløsning.
Nebuliser solution.
Inhalator (ABS/PE/PP)
inhaler (ABS/PE/PP)
inhalator (plastik/
inhaler (plastic/stainless steel)
inhalator (plastik/rustfri t stål)
inhaler (plastic/ stainless steel)
inhalator (polycarbonat /rustfrit stål )
inhaler (polycarbonate/stainless steel)
inhalator (polycarbonat /rustfrit stål ) inhalator (polycarbonat /rustfrit stål )
inhaler (polycarbonate/stainless steel) inhaler (polycarbonate/stainless steel)
Inhalator Blisterkort Inhalatorens underdel
Inhaler Blister card Inhaler base
inhalator indeholdende 120 doser. inhalatorer, der hver indeholder 120 doser.
inhaler containing 120 doses. inhalers each containing 120 doses.
inhalator indeholdende 60 doser.
inhaler containing 60 doses. inhalers each containing 60 doses.
inhalator indeholdende 60 doser. inhalatorer, der hver indeholder 60 doser.
inhaler containing 60 doses. inhalers each containing 60 doses.
Inhalator Inhalator
inhaler
inhalator(120 doser) inhalatorer (2x120 doser)
2 inhalers (2x120 doses)
Inhalatoranordningen er en anordning med flere komponenter, der er fremstillet af polycarbonat, acrylonitril-butadien-styren, polyoxymethylen, polyesterbutylenterephthalat, polypropylen, polystyren og rustfrit stål.
The inhaler device is a multicomponent device made of polycarbonate, acrylonitrile-butadiene- styrene, polyoxymethylene, polyester-butylene-terephthalate, polypropylene, polystyrene and stainless steel.
Inhalatoren afgiver 22 µg vilanterol og 55 µg umeclidinium (som umeclidiniumbromid) for hver inhalation.
The inhaler delivers 22 micrograms of vilanterol and 55 micrograms of umeclidinium (as umeclidinium bromide) with each inhalation.
Inhalatoren afgiver 22 µg vilanterol og 55 µg umeclidinium (som umeclidiniumbromid) for hver inhalation.
The inhaler delivers 22 micrograms of vilanterol and 65 micrograms of umeclidinium bromide (equivalent to 55 micrograms of umeclidinium) with each inhalation.
Inhalatoren indeholder to laminerede aluminiumsfolie-strips (en for hvert aktivt stof) med enten 14 eller 30 doser.
The inhaler contains two aluminium foil laminate strips of 14 or 30 doses.
Inhalatoren indeholder to laminerede aluminiumsfolie–blister (en for hvert aktivt stof) med enten 7 eller 30 doser.
The inhaler contains two aluminium foil laminate blisters of 7 or 30 doses.
Inhalatoren indeholder to laminerede aluminiumsfolie–strips (en for hvert aktivt stof) med enten 14 eller 30 doser.
The inhaler contains two aluminium foil laminate strips of 14 or 30 doses.
Inhalatoren leveres forseglet i en beskyttende pose af aluminium-laminat, som indeholder en lille pose med tørremiddel, anbragt i en papkarton.
The inhaler is supplied sealed in a protective aluminium laminate pouch containing a desiccant sachet, placed in a cardboard carton.
Inhalatoren skal holdes tør.
Keep the inhaler dry.
Inhalatoren skal opbevares i den forseglede bakke for at beskytte mod fugt og tages først ud umiddelbart inden den skal anvendes første gang.
Keep the inhaler inside the sealed tray in order to protect from moisture and only remove immediately before first use.
Inhalatoren skal opbevares i den forseglede bakke for at beskytte mod fugt og tages først ud umiddelbart inden den skal anvendes første gang.
Keep the inhaler inside the sealed tray to protect from moisture and only remove immediately before first use.
Inhalatoren vil være i 'lukket' position, når den tages ud af den forseglede bakke.
The inhaler will be in the ‘closed’ position when it is first taken out of its sealed tray.
Inhalatoren vil være i ”lukket” position, når den tages ud af den forseglede bakke.
When the inhaler is taken out of its tray, it will be in the ‘closed’ position.
inhalatorer, der hver indeholder 60 doser. inhalatorer, der hver indeholder 60 doser.
3 inhalers each containing 60 doses.
Inhaler
Inhale
Inhaler indholdet af 4 kapsler to gange daglig som følger:
Inhale the content of 4 capsules twice a day as follows:
Inhaler kapslen – 1. åndedrag
Inhale the capsule – 1st breath:
Inhaler kapslen – 2. åndedrag
Inhale the capsule – 2nd breath:
Inhaler kapslens indhold ved hjælp af inhalatoren med en til to indåndinger.
Inhale the contents of the capsule using the inhaler, with one or two breaths in.
Inhaler medicinen
Inhale the medicine
Inhaler medicinen igen ved at gentage trin 8 og 9.
Inhale the medicine again by repeating steps 8 and 9.
Inhaler medicinen igen ved at gentage trin 9 og 10.
Inhale the medicine again by repeating steps 9 and 10.
Inhaler medicinen:
Inhale the medicine:
inhalerede steroider, anvendes til at behandle høfeber (allergisk rhinitis):
inhaled steroids, used to treat hay fever (allergic rhinitis):
Inhalerede/nasale kortikosteroider
Inhaled/Nasal corticosteroids
Inhalerede/nasale kortikosteroider: Budesonid, fluticason
Inhaled/nasal corticosteroids: Budesonide, fluticasone
Inhaleret aclidiniumbromid virker lokalt i lungerne på M3-receptorer og medfører bronkodilatation.
Inhaled aclidinium bromide acts locally in the lungs to antagonise M3 receptors of airway smooth muscle and induce bronchodilation.
INHALERET BETA-AGONIST
INHALED BETA AGONISTS
Inhaleret humant insulin absorberes hurtigere hos ældre forsøgspersoner med type 2 diabetes end sub- kutant administreret hurtigtvirkende humant insulin.
In older subjects with type 2 diabetes, inhaled human insulin was absorbed more rapidly than subcutaneously administered fast-acting human insulin.
Inhaleret humant insulin kan anvendes alene eller i kombination med orale antidiabetika og/eller langtidsvirkende eller middellangtvirkende insuliner indgivet subkutant for at optimere glykæmisk kontrol.
Inhaled human insulin may be used alone or in combination with oral antidiabetic agents and/or long or intermediate acting subcutaneously administered insulins to optimise glycaemic control.
Inhaleret insulin Subcutaneous Insulin
Inha le d Insulin
Inhaleret korrekt RØD
Inhaled correctly RED